Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 17/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11121976 | 0.90 | ALKBH5 (0.50) | ALKBH5ALDH1A1KDM4ECTSA | |
| SCHEMBL8990040 | 0.86 | ALDH1A1 (0.43) | ALKBH5ALDH1A1KDM4ECTSAMEN1 | |
| SCHEMBL10956802 | 0.84 | ALKBH5 (0.58) | ALKBH5ALDH1A1KDM4ECTSA | |
| SCHEMBL8990086 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KDM4ECTSAMEN1LMNA | |
| SCHEMBL692667 | 0.81 | MAPT (0.52) | ALDH1A1KDM4EMEN1LMNAKMT2A | |
| SCHEMBL10400766 | 0.81 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL6053229 | 0.81 | KDM4E (0.30) | ALDH1A1KDM4E | |
| SCHEMBL1266657 | 0.80 | ALKBH5 (0.51) | ALKBH5ALDH1A1KDM4ECTSA | |
| SCHEMBL9786518 | 0.78 | NOX4 (0.44) | ALDH1A1KDM4EMEN1LMNAKMT2A | |
| SCHEMBL8990138 | 0.78 | ATAD2 (0.36) | ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7988740-B2 | Keratin dyeing compositions comprising a radical scavenger and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2011-08-02 | — | — | US | claimed |
| US-20110035885-A1 | Keratin Dyeing Compositions Comprising a Radical Scavenger and Use Thereof | NOXELL CORPORATION | 2011-02-17 | — | — | US | claimed |
| US-7988740-B2 | Keratin dyeing compositions comprising a radical scavenger and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7902144-B2 | Carrier-molecule-affinitive substance which has an association constant KA relative to a carrier molecule greater than 103 M-1 via a noncovalent bond | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20110035885-A1 | Keratin Dyeing Compositions Comprising a Radical Scavenger and Use Thereof | NOXELL CORPORATION | 2011-02-17 | — | — | US | disclosed |
| EP-1272223-B1 | THERAPEUTIC AND DIAGNOSTIC LIGAND SYSTEMS COMPRISING TRANSPORT MOLECULE BINDING PROPERTIES AND MEDICAMENTS CONTAINING THE SAME | KTB TUMORFORSCHUNGS GMBH (DE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1051655-B1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20030185793-A1 | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same | Vergell Medical S.A. (CH) | 2003-10-02 | — | — | US | disclosed |
| EP-1051655-A4 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1272223-A1 | THERAPEUTIC AND DIAGNOSTIC LIGAND SYSTEMS COMPRISING TRANSPORT MOLECULE BINDING PROPERTIES AND MEDICAMENTS CONTAINING THE SAME | KTB Tumorforschungsgesellschaft mbH (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001068142-A1 | THERAPEUTIC AND DIAGNOSTIC LIGAND SYSTEMS COMPRISING TRANSPORT MOLECULE BINDING PROPERTIES AND MEDICAMENTS CONTAINING THE SAME | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2001-09-20 | — | — | WO | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-4225492-A | Water-soluble disazo dyestuffs, prepared from unsymmetrical heterocyclic diamines | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-09-30 | — | — | US | disclosed |
| US-4144231-A | Soluble trisazo dyestuffs containing a 2-phenyl-benzimidazolyl, -benzoxazolyl or -benzthiazolyl middle component | CASSELLA AKTIENGESELLSCHAFT (DE) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185793-A1 | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same | SLCO1B1, SLCO1B3, SLCO1A2 | ALKBH5 3594/4885ALDH1A1 1054/4885KDM4E 4710/4885 |
| US-20110035885-A1 | Keratin Dyeing Compositions Comprising a Radical Scavenger and Use Thereof | KRT18, LPO, CYB5R3 | ALKBH5 413/4885ALDH1A1 326/4885KDM4E 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.